PerpEquities

Laporan laba rugi Viking Therapeutics, Inc. (VKTX)

NASDAQ · Healthcare · Biotechnology · Karyawan: 53 · CEO: Brian Lian

Harga
$27,28 +1,56%
Kapitalisasi pasar
$3,48 M
Nilai perusahaan
$3,06 M
Laporan terakhir
Q3 '26 diajukan 2026-10-29
Laporan berikutnya
2027-02-10 Estimasi EPS: -$1,38

Laporan laba rugi

Laporan laba rugiTrenQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Beban pokok pendapatan$0$0$0$0$0$0$0$114 rb$94 rb$0$0$0
Laba kotor$0$0$0$0$0$0$0-$114 rb-$94 rb$0$0$0
Riset & pengembangan$20,5 jt$24,1 jt$23,8 jt$22,8 jt$31 jt$41,4 jt$60,2 jt$90 jt$153 jt$150 jt$116 jt$167 jt
Umum & administrasi$8,78 jt$9,97 jt$10,3 jt$13,8 jt$15,3 jt$14,1 jt$14,4 jt$8,61 jt$11,3 jt$14 jt$16,8 jt$20,3 jt
Beban operasional$29,3 jt$34,1 jt$34,1 jt$36,6 jt$46,2 jt$55,5 jt$74,6 jt$98,6 jt$165 jt$164 jt$133 jt$187 jt
Laba operasional-$29,3 jt-$34,1 jt-$34,1 jt-$36,6 jt-$46,2 jt-$55,5 jt-$74,6 jt-$98,6 jt-$165 jt-$164 jt-$133 jt-$187 jt
Pendapatan bunga$4,71 jt$6,75 jt$11,8 jt$11,5 jt$10,8 jt$9,86 jt$9,03 jt$7,77 jt$7,04 jt$5,8 jt$4,55 jt$4,01 jt
Beban bunga$26 rb$28 rb$18 rb$24 rb$24 rb$24 rb$24 rb$8 rb$0$0$0$88 rb
Pendapatan non-operasional lainnya (keuntungan investasi, kurs ...)-$4,71 jt-$6,75 jt-$11,8 jt-$11,6 jt-$10,8 jt-$9,86 jt-$9,04 jt-$7,78 jt-$7,08 jt-$5,8 jt-$4,58 jt-$4,01 jt
Total pendapatan non-operasional$4,68 jt$6,72 jt$11,8 jt$11,6 jt$10,8 jt$9,84 jt$9,01 jt$7,77 jt$7,08 jt$5,8 jt$4,58 jt$3,93 jt
Laba sebelum pajak-$24,6 jt-$27,4 jt-$22,3 jt-$24,9 jt-$35,4 jt-$45,6 jt-$65,6 jt-$90,8 jt-$158 jt-$158 jt-$128 jt-$183 jt
Laba bersih-$24,6 jt-$27,4 jt-$22,3 jt-$24,9 jt-$35,4 jt-$45,6 jt-$65,6 jt-$90,8 jt-$158 jt-$158 jt-$128 jt-$183 jt
EPS (dasar)-$0,25-$0,26-$0,20-$0,22-$0,32-$0,41-$0,58-$0,81-$1,38-$1,37-$1,10-$1,55
EPS (dilusian)-$0,25-$0,26-$0,20-$0,22-$0,32-$0,41-$0,58-$0,81-$1,38-$1,37-$1,10-$1,55
Saham (dasar, rata-rata tertimbang)100 jt103 jt110 jt111 jt111 jt112 jt112 jt112 jt114 jt116 jt116 jt118 jt
Saham (dilusian, rata-rata tertimbang)100 jt103 jt110 jt111 jt111 jt112 jt112 jt112 jt114 jt116 jt116 jt118 jt
Depresiasi & amortisasi$74 rb$74 rb$75 rb$87 rb$110 rb$111 rb$112 rb$114 rb$94 rb$85 rb$157 rb$0
EBITDA-$24,5 jt-$27,3 jt-$22,2 jt-$24,8 jt-$35,3 jt-$45,5 jt-$65,4 jt-$90,7 jt-$158 jt-$158 jt-$128 jt-$183 jt

Distandardisasi dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Pendapatan, laba operasional, dan pertumbuhan

kuartalan

Margin

kuartalan

Biaya sebagai % pendapatan

kuartalan

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data per 2026-11-02